ClinicalTrials.gg

Program

NNC0537-1482

A development code.

Its studies are mostly in Heart Failure · Renal Insufficiency, Chronic, led by Novo Nordisk.

Furthest: phase 1, since Oct 2, 20243 company-led studies, 2 open or runningNext primary completion: Jan 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk32 open or runningphase 1since Oct 2, 2024Oct 2, 2024Jan 15, 2027phase 1 · NCT07218627

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 2, 2024First study: phase 1 study in Heart FailureFirst studyNCT06625307 · 31 enrolled · Netherlands
  2. Oct 16, 2025Phase 1 study in Heart FailureNCT07218627 · 36 planned · United Kingdom
  3. Sep 2, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07808788 · 54 planned · Germany

Ahead

  1. Jan 15, 2027Primary completion: phase 1 study in Heart FailureNCT07218627
  2. Jul 6, 2027Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07808788

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07808788Renal Insufficiency, Chronic · Germany1Not yet recruitingJul 6, 202754
NCT07218627Heart Failure · United Kingdom1RecruitingJan 15, 202736
NCT06625307Heart Failure · Netherlands1CompletedMay 4, 202531

How it is read

Names in the registry

  • “NNC0537-1482”, 3 entries

Codes read as this program: NNC05371482.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.